Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alan J. Xiao"'
Publikováno v:
Journal of Clinical Pharmacology
Ceftolozane/tazobactam is an antipseudomonal antibacterial approved for the treatment of complicated urinary tract infections (cUTIs) and complicated intra‐abdominal infections (cIAIs) and in phase 3 clinical development for treatment of nosocomial
Publikováno v:
International journal of antimicrobial agents. 52(3)
Ceftolozane/tazobactam is approved for treatment of complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI) with renal function-based dose adjustment. Given that creatinine clearance, body weight and sex are highly
Publikováno v:
SPE Journal. 9:280-289
SummarySignificant progress has been made toward developing a quantitative understanding of the inhibitor/rock interaction. In this study, four common oil field inhibitors (three phosphonates and one polyacrylate) are compared using carbonate-rich fo
Autor:
Maria Gutierrez, Kenneth Willson, Lucas Van Bortel, S.R. Sinclair, Rebecca L. Blanchard, John Palcza, T Laethem, Lisa Hickey, Jacqueline B. McCrea, Susan Ermlich, Tae H. Han, Deborah Panebianco, Christopher Lines, Janet Boyle, Yang Xu, Alan J Xiao, M. Gail Murphy
Publikováno v:
Journal of clinical pharmacology. 50(12)
Telcagepant is a novel, orally active, and selective calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine with and without aura. Three separate clinical studies were conducted to evaluate the pharmacokin
Publikováno v:
Infectious Diseases and Therapy
Introduction Ceftolozane/tazobactam is an antibacterial agent with potent in vitro activity against Gram-negative pathogens, including many extended-spectrum β-lactamase-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa. Because